Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 44 citing articles:

The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Taoming Liu, Sheng Li, Shuni Ying, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 224
Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 16
GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets
Nick Dand, Philip E. Stuart, John Bowes, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
The biological basis of disease recurrence in psoriasis: a historical perspective and current models
L. Puig, Antonio Costanzo, Ernesto J. Muñoz‐Elías, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 5, pp. 773-781
Open Access | Times Cited: 60
Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
M. Masson Regnault, Jason Shourick, Fatma Jendoubi, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 4, pp. 433-447
Open Access | Times Cited: 45
Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence
Xiaoying Sun, Ziyang Cui, Qingyun Wang, et al.
Autoimmunity Reviews (2024) Vol. 23, Iss. 4, pp. 103530-103530
Closed Access | Times Cited: 10
Brodalumab: 5-Year US Pharmacovigilance Report
Mark Lebwohl, John Koo, April W. Armstrong, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 5, pp. 1349-1357
Open Access | Times Cited: 10
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 829-842
Open Access | Times Cited: 9
GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets
Nick Dand, Philip E. Stuart, John Bowes, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 18
Interleukin inhibitors and the associated risk of candidiasis
Sabir Khan, Hazrat Bilal, Muhammad Nadeem Khan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis
S. Wu, Yuanyuan Xu, Lihua Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3545-3545
Open Access | Times Cited: 11
Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management
Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, et al.
Mycology: An International Journal on Fungal Biology (2023) Vol. 15, Iss. 1, pp. 30-44
Open Access | Times Cited: 11
Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
Dimitrios Rigopoulos, Eleftheria Tampouratzi, Charalampos Angelakopoulos, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 6, pp. 1121-1130
Closed Access | Times Cited: 4
A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
Ke He, Kaidi Zhao, Tingyi Yin, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study
Luca Potestio, Fabrizio Martora, Flavia Raia, et al.
Dermatology and Therapy (2025)
Open Access
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy
Marco Galluzzo, Giacomo Caldarola, Clara De Simone, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 9, pp. 1299-1310
Open Access | Times Cited: 24
Brodalumab in plaque psoriasis: Real‐world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks
Natalia Rompoti, Maria Politou, Irene Stefanaki, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 4, pp. 689-697
Closed Access | Times Cited: 18
Brodalumab: 4-Year US Pharmacovigilance Report
Mark Lebwohl, John Koo, Craig L. Leonardi, et al.
Journal of Drugs in Dermatology (2023) Vol. 22, Iss. 4, pp. 419-422
Open Access | Times Cited: 10
Gastroenterological safety of IL-17 inhibitors: a systematic literature review
Bénédicte Caron, Jean‐Yves Jouzeau, Pierre Miossec, et al.
Expert Opinion on Drug Safety (2021) Vol. 21, Iss. 2, pp. 223-239
Closed Access | Times Cited: 23
Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms
Joshua H. K. Tam, Philip C. Robinson, Peter Nash
Current Rheumatology Reports (2022) Vol. 24, Iss. 10, pp. 310-320
Open Access | Times Cited: 15
Two-Year US Pharmacovigilance Report on Brodalumab
Mark Lebwohl, Craig L. Leonardi, Jashin J. Wu, et al.
Dermatology and Therapy (2020) Vol. 11, Iss. 1, pp. 173-180
Open Access | Times Cited: 20
An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis
Magdalena Kutwin, Monika Migdalska‐Sęk, Ewa Brzeziańska‐Lasota, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 24, pp. 5834-5834
Open Access | Times Cited: 16
Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies
Jensen Yeung, Paul E. Bunce, Charles Lynde, et al.
Journal of Cutaneous Medicine and Surgery (2022) Vol. 26, Iss. 1_suppl, pp. 3S-23S
Closed Access | Times Cited: 11
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
Kristian Reich, Luca Bianchi, A. Khemis, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 2, pp. 453-468
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top